Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression

European Journal of Pharmacology

Volumn 592, Issue 1-3, 2008, Pages 96-102

  Bespalov, Anton Y ^a   van Gaalen, Marcel M ^a   Sukhotina, Irina A ^b   Wicke, Karsten ^a   Mezler, Mario ^a   Schoemaker, Hans ^a   Gross, Gerhard ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Animal model; Anxiety; Depression; LY 341495; Metabotropic glutamate receptor

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; AMPHETAMINE; CHLORDIAZEPOXIDE; DIAZEPAM; FLUOXETINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR ANTAGONIST; METHAMPHETAMINE; PAROXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFECT; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HYPERTHERMIA; INSTRUMENTAL CONDITIONING; LIGHT DARK CYCLE; MALE; MARBLE BURYING TEST; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS; TRANQUILIZING ACTIVITY;

AMINO ACIDS; AMPHETAMINE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DARKNESS; DEPRESSION; DIAZEPAM; FEVER; FLUOXETINE; LIGHT; MALE; MICE; PAROXETINE; RECEPTORS, METABOTROPIC GLUTAMATE; REINFORCEMENT SCHEDULE; STRESS, PSYCHOLOGICAL; XANTHENES;

EID: 49949084013     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.089     Document Type: Article

References (36)

1. Bespalov A., Jongen-Relo A.L., van Gaalen M., Harich S., Schoemaker H., and Gross G. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J. Pharmacol. Exp. Ther. 320 (2007) 944-950
2. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., Yoshimizu T., Yasuhara A., Sakagami K., Okuyama S., Nakanishi S., and Nakazato A. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46 (2004) 457-467
3. Crabbe J.C., Wahlsten D., and Dudek B.C. Genetics of mouse behavior: interactions with laboratory environment. Science 284 (1999) 1670-1672
4. Crawley J., and Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13 (1980) 167-170
5. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., and van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 17 (2003) 2409-2417
6. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., and Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33 (2007) 1603-1610
7. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., and Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 318 (2006) 173-185
8. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
9. Grillon C., Cordova J., Levine L.R., and Morgan III C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 168 (2003) 446-454
10. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., and Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284 (1998) 651-660
11. Hill M.N., and Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15 (2005) 593-599
12. Iijima M., Shimazaki T., Ito A., and Chaki S. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl) 190 (2007) 233-239
13. Karasawa J., Yoshimizu T., and Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci. Lett. 393 (2006) 127-130
14. Klodzinska A., Chojnacka-Wojcik E., Palucha A., Branski P., Popik P., and Pilc A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 (1999) 1831-1839
15. Lavreysen H., and Dautzenberg F.M. Therapeutic potential of group III metabotropic glutamate receptors. Curr. Med. Chem. 15 (2008) 671-684
16. Lee Y., Duman R.S., and Marek G.J. The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. Neurosci. Lett. 398 (2006) 328-332
17. Linden A.M., Greene S.J., Bergeron M., and Schoepp D.D. Anxiolytic activity of the mGlu2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29 (2004) 502-513
18. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92 (1987) 180-185
19. Marco E.M., Perez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., File S.E., and Viveros M.P. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15 (2004) 21-27
20. Navarro M., Hernandez E., Munoz R.M., del A I., Villanua M.A., Carrera M.R., and Rodriguez d.F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8 (1997) 491-496
21. Nicolas L.B., Kolb Y., and Prinssen E.P.M. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur. J. Pharmacol 547 (2006) 106-115
22. Njung'e K., and Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 38 (1991) 63-67
23. O'Donnell J.M., and Seiden L.S. Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs. J. Pharmacol. Exp. Ther. 224 (1983) 80-88
24. O'Neill M.F., Heron-Maxwell C., Conway M.W., Monn J.A., and Ornstein P. Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45 (2003) 565-574
25. Ornstein P.L., Bleisch T.J., Arnold M.B., Kennedy J.H., Wright R.A., Johnson B.G., Tizzano J.P., Helton D.R., Kallman M.J., Schoepp D.D., and Herin M. 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. J. Med. Chem. 41 (1998) 358-378
26. Palucha A., Tatarczynska E., Branski P., Szewczyk B., Wieronska J.M., Klak K., Chojnacka-Wojcik E., Nowak G., and Pilc A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 46 (2004) 151-159
27. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
28. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., and Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6 (2003) 189-197
29. Shekhar A., and Keim S.R. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39 (2000) 1139-1146
30. Shimazaki T., Iijima M., and Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur. J. Pharmacol. 501 (2004) 121-125
31. Sokolowski J.D., and Seiden L.S. The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology (Berl) 147 (1999) 153-161
32. Spooren W.P., Schoeffter P., Gasparini F., Kuhn R., and Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 435 (2002) 161-170
33. Van Der Heyden J.A., Zethof T.J., and Olivier B. Stress-induced hyperthermia in singly housed mice. Physiol. Behav. 62 (1997) 463-470
34. Witkin J.M., Monn J.A., Brittion T., Ornstein P., Li X., Johnson B.G., Baez M., Alt A., Schoepp D.D., and Marek G.J. Further evidence for a metabotropic glutamate group II antagonist mechanism for the induction of antidepressant-like effects in rodents. Neuropsychopharmacology 31 Suppl 1 (2006) S166
35. Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., and Schoepp D.D. Binding of [3H](2S,1′S,2′S)-2-(9-xanthylmethyl)-2-(2′-carboxycycl opropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 546-554
36. Yoshimizu T., Shimazaki T., Ito A., and Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186 (2006) 587-593